Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(1.33)
# 3,544
Out of 4,547 analysts
124
Total ratings
38.2%
Success rate
-0.6%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QNCX Quince Therapeutics | Initiated Coverage: Buy | $80 | $18.78 | +325.99% | 1 | Jun 25, 2026 | |
| TENX Tenax Therapeutics | Maintained: Buy | $35 | $15.72 | +122.65% | 2 | Jun 24, 2026 | |
| INSM Insmed | Maintained: Buy | $230 → $235 | $108.62 | +116.35% | 3 | Jun 10, 2026 | |
| CNTB Connect Biopharma Holdings | Initiated Coverage: Buy | $4 | $2.21 | +81.00% | 1 | May 21, 2026 | |
| IKT Inhibikase Therapeutics | Maintained: Buy | $4 | $2.23 | +79.37% | 2 | May 18, 2026 | |
| PTHS Pelthos Therapeutics | Initiated Coverage: Buy | $50 | $26.86 | +86.15% | 1 | Apr 1, 2026 | |
| CTMX CytomX Therapeutics | Maintained: Buy | $10 → $12 | $3.42 | +250.88% | 5 | Mar 20, 2026 | |
| GOSS Gossamer Bio | Downgraded: Hold | n/a | $0.1548 | - | 6 | Mar 20, 2026 | |
| UTHR United Therapeutics | Initiated Coverage: Buy | $525 → $625 | $535.83 | +16.64% | 4 | Mar 12, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintained: Buy | $85 | $59.21 | +43.56% | 18 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 | $5.48 | +100.73% | 5 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $450 → $400 | $271.37 | +47.40% | 11 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $4.05 | n/a | 4 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $480 | $482.00 | n/a | 23 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $405 → $340 | $366.24 | n/a | 4 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $52 → $55 | $60.93 | n/a | 8 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $70 → $80 | $130.28 | n/a | 8 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $795 → $925 | $675.19 | n/a | 4 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $10 | $15.64 | n/a | 6 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $9.53 | n/a | 1 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $48.15 | n/a | 3 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 | $5.16 | n/a | 4 | Mar 20, 2023 |
Quince Therapeutics
Jun 25, 2026
Initiated Coverage: Buy
Price Target: $80
Current: $18.78
Upside: +325.99%
Tenax Therapeutics
Jun 24, 2026
Maintained: Buy
Price Target: $35
Current: $15.72
Upside: +122.65%
Insmed
Jun 10, 2026
Maintained: Buy
Price Target: $230 → $235
Current: $108.62
Upside: +116.35%
Connect Biopharma Holdings
May 21, 2026
Initiated Coverage: Buy
Price Target: $4
Current: $2.21
Upside: +81.00%
Inhibikase Therapeutics
May 18, 2026
Maintained: Buy
Price Target: $4
Current: $2.23
Upside: +79.37%
Pelthos Therapeutics
Apr 1, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $26.86
Upside: +86.15%
CytomX Therapeutics
Mar 20, 2026
Maintained: Buy
Price Target: $10 → $12
Current: $3.42
Upside: +250.88%
Gossamer Bio
Mar 20, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.1548
Upside: -
United Therapeutics
Mar 12, 2026
Initiated Coverage: Buy
Price Target: $525 → $625
Current: $535.83
Upside: +16.64%
BioMarin Pharmaceutical
Mar 2, 2026
Maintained: Buy
Price Target: $85
Current: $59.21
Upside: +43.56%
Feb 23, 2026
Maintained: Buy
Price Target: $11
Current: $5.48
Upside: +100.73%
Feb 12, 2026
Maintained: Hold
Price Target: $450 → $400
Current: $271.37
Upside: +47.40%
Mar 20, 2025
Maintained: Buy
Price Target: $9
Current: $4.05
Upside: n/a
Feb 11, 2025
Reiterated: Buy
Price Target: $480
Current: $482.00
Upside: n/a
Feb 5, 2025
Maintained: Buy
Price Target: $405 → $340
Current: $366.24
Upside: n/a
Feb 4, 2025
Maintained: Hold
Price Target: $52 → $55
Current: $60.93
Upside: n/a
Nov 6, 2024
Maintained: Hold
Price Target: $70 → $80
Current: $130.28
Upside: n/a
Apr 17, 2024
Maintained: Hold
Price Target: $795 → $925
Current: $675.19
Upside: n/a
Feb 23, 2024
Maintained: Buy
Price Target: $15 → $10
Current: $15.64
Upside: n/a
Nov 10, 2023
Downgraded: Hold
Price Target: n/a
Current: $9.53
Upside: n/a
Oct 17, 2023
Downgraded: Hold
Price Target: n/a
Current: $48.15
Upside: n/a
Mar 20, 2023
Maintained: Hold
Price Target: $3
Current: $5.16
Upside: n/a